Research & Clinical Trials
Anteris Reports 1% Heart Failure Hospitalization at One Year in 100 Small-Annulus DurAVR Patients
By News Desk ·
Key takeaways
- Anteris reported that 1% of 100 DurAVR patients with small aortic annuli were hospitalized for heart failure at one year.
- The one-year mean pressure gradient was 8.9 mmHg, with no valve-related deaths or moderate or severe paravalvular leaks.
- The PARADIGM pivotal trial of DurAVR is actively enrolling, and Anteris received French ANSM clearance in June 2026 to expand it to France.
Anteris Technologies Global Corp. reported one-year DurAVR outcomes in 100 patients with small aortic annuli, including a 1% rate of heart failure hospitalization, a mean pressure gradient of 8.9 mmHg and no valve-related deaths. TradingView published the results on November 22, 2026.
Inside the DurAVR One-Year Results
Anteris Technologies is a pre-revenue structural heart device company developing the DurAVR biomimetic transcatheter heart valve system, built on its ADAPT anti-calcification tissue, for patients with severe calcific aortic stenosis.
The 100 patients in the one-year analysis had small aortic annuli. The company said no moderate or severe paravalvular leaks were observed in the cohort, and that 97% of patients were free from moderate or severe paravalvular leak at 30 days.
The findings pool patients from the EMBARK study and an early feasibility study rather than the pivotal program. The company said the PARADIGM pivotal trial is actively enrolling.
Anteris Manufacturing and Regulatory Steps
According to akta.pro company records, Anteris entered an 11-year lease for approximately 181,436 sq ft of office and warehouse space in Brooklyn Park, Minnesota, beginning September 1, 2026, to scale U.S. manufacturing and operations. The same records show the company received full regulatory clearance from French ANSM in June 2026 to expand the PARADIGM pivotal trial to France.
Anteris completed $320 million in aggregate capital raises in January 2026, including a $200 million public offering at $5.75 per share and a $90 million private placement to Medtronic for a 16-19.99% stake, according to the same records.
Earlier Anteris Financial Disclosures
Anteris reported net operating cash outflows of $20.8 million in the second quarter of 2026, driven by clinical, regulatory and manufacturing costs supporting the PARADIGM trial, Stock Titan reported in August 2026. MarketScreener reported the same month that Anteris's net loss narrowed and net sales rose in the quarter.
Assenagon Asset Management S.A. invested approximately $6.35 million in Anteris by acquiring 644,668 shares during the second quarter, Defense World reported in August 2026.
What Comes Next for PARADIGM
Anteris received French ANSM clearance in June 2026 to expand the trial to France.